Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

ainful and swollen joints, unexplained fever, skin rash, and kidney problems. Lupus can lead to arthritis, kidney failure, heart and lung inflammation, central nervous system abnormalities, inflammation of the blood vessels, and blood disorders. For more information on lupus, visit the Lupus Foundation of America at www.lupus.org, the European Lupus Erythematosus Federation at www.elef.rheumanet.org, or the National Institute of Arthritis and Musculoskeletal and Skin Diseases at www.niams.nih.gov.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company's primary focus is rapid progress toward the commercialization of its two lead compounds, Albuferon for hepatitis C and LymphoStat-B for lupus -- both of which are in Phase 3 clinical trials.

In June 2006, HGS announced that the U.S. government exercised its option under an existing contract to purchase 20,000 doses of ABthrax(TM) for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of hematologic and solid malignancies, in addition to an antibody to the CCR5 receptor for the treatment of HIV/AIDS.

For more information about HGS, visit www.hgsi.com. For more information on LymphoStat-B, visit www.hgsi.com/products/LSB.html. Health professionals or patients interested in LymphoStat-B clinical trials or other studies involving HGS products may inquire via the "Conta
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... application process, CSA Medical, Inc. ( www.CSAmedical.com ) has ... future plans for its proprietary spray cryotherapy platform on ... will take place from 10:20-10:50 am at the Walter ... CSA Medical is first to harness the power of ...
... EMERYVILLE, Calif., Oct. 7 Onyx Pharmaceuticals, Inc. (Nasdaq: ... teleconference to provide a status update on its New Drug ... webcast of the presentation on our website at: ... 847-585-4405 and using the passcode 28119641. A replay of the ...
Cached Medicine Technology:CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference 2Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib 2
(Date:4/23/2014)... 2014 Pregnant immigrants from Sub-Saharan Africa, Latin ... during pregnancy, according to new research from St. ... the British Journal of Obstetrics and Gynaecology ... rates among immigrants and native-born women in six ... Sweden, Spain (Catalonia and Valencia) and the United ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... that rats exposed to high-energy particles, simulating conditions astronauts ... lapses in attention and slower reaction times, even when ... , The cognitive impairments which affected a large ... appear to be linked to protein changes in the ... hold true in humans, suggest it may be possible ...
(Date:4/23/2014)... BUFFALO, N.Y. A novel compound that targets an ... host of cocaine addiction behaviors, including relapse behavior, a ... research provides strong evidence that this may be a ... no effective medications exist., The UB research was published ... last week. , In the study, the compound, RO5263397, ...
(Date:4/23/2014)... could help doctors predict which patients might suffer potentially ... The program, which assesses brain scans using pattern recognition ... passport control, has been developed by researchers at Imperial ... the Wellcome Trust, which used the software are published ... Stroke affects over 15 million people each year worldwide. ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
... of expertise and other factors when ... ... CIGNA Behavioral Health,(CBH) members can now view robust, online ... including license,levels, languages spoken, educational background, areas of specialization,and years ...
... -- Researchers at Mayo Clinic in Jacksonville have discovered how ... proteins in the brain, resulting in a common dementia, ... number of age-related neurological disorders. , In the Sept. ... that absence of a gene known as progranulin leads to ...
... be on,display throughout The Kroger Co.,s (NYSE: KR ... partners with vendors and suppliers to support,National Breast Cancer ... tags can be found on shelves in Kroger,stores across ... support breast cancer awareness in their community. Several of,Kroger,s ...
... Climb to Conquer Cancer will follow four professional U.S., ... Alaska, NEW YORK, Sept. 27 Fred Hutchinson ... expedition to an unclimbed,mountain in the name of cancer ... expedition. The inaugural Climb to Conquer Cancer, performed ...
... QMed, Inc.,(Nasdaq: QMED ) today announced it ... August 31, 2007 revenue of approximately $10.8 million and,$26.6 ... $13 million,respectively. The Company,s cash position as of August ... Jane Murray, president and CEO, said, "During the ...
... Edition Strawberry Jelly Krimpets Will Benefit Online ... for Breast Cancer Support and Information, PHILADELPHIA, Sept. ... philanthropic product offering, the,Tastykake Strawberry Jelly Krimpet. 10% of ... will be donated to breastcancer.org, a,Narberth, Pennsylvania based online ...
Cached Medicine News:Health News:CIGNA Behavioral Health Offers Members Online Provider Profiles 2Health News:Loss of gene leads to protein splicing and buildup of toxic proteins in neurons 2Health News:Kroger 'Pink Tag' Campaign to Raise $2.5 Million for Breast Cancer Awareness in October 2Health News:Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 3Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 2Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 3
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... wide range of Platelet aggregometers allows ... meet particular needs. Single, dual and ... chart recorder outputs or digital computer ... Optical aggregometers, which measure platelet aggregation ...
... you in achieving improved cost efficiency ... to cut costs is constantly increasing. ... eliminate unnecessary manual interactions. Ensuring security ... control mechanisms like pipetting integrity check. ...
... Advia 2400 has minimal ... (as low as 2 ... (40 L/hour) thus maximizing ... universal rack handler facilitates ...
Medicine Products: